The Food and Drug Administration has approved special handling instructions to allow health care providers to use certain opioid and other intravenous drug products made by Hospira that were on hold due to low potential for a manufacturing defect but are in short supply. Health care providers should not use the Carpuject Luer Lock Glass Syringe products if the cartridges are visibly damaged or contain particulate matter, according to the instructions. Hospitals and health systems continue to experience critical shortages of a number of injectable opioid medications. Commenting this month on a Drug Enforcement Administration proposed rule on controlled substances quotas, AHA urged the agency to include drug shortages as a factor when setting and adjusting aggregate and individual manufacturers’ production quotas for controlled substances, and joined with the American Society of Health-System Pharmacists and others in requesting similar changes to the proposed rule.

Related News Articles

Headline
The Government Accountability Office yesterday released a report calling for the Department of Health and Human Services to improve its efforts responding to…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,…
Headline
In this conversation, Matthew Hoag, director of integrated behavioral health at Denver Health, shares how the organization is innovating through integration to…
Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…